Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer
Phase III Randomised Study Of Adjuvant Paclitaxel And Carboplatin (TAXOL-PARAPLATINE) With Concomittant Radiotherapy In Patients With Stage II or III Non-Metastatic Non-Small Cell Lung Cancer
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
This PHASE3 trial investigates Lung Cancer and is currently ongoing. GERCOR - Multidisciplinary Oncology Cooperative Group leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2018 [monthly]
Unknown Status PHASE3
First recorded
Jun 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Annecy, France , Avignon, France , Bayeux, France , Bayonne, France , Beauvais, France , Bobigny, France , Bois-Guillaume, France , Bordeaux, France , Boucher, France , Caen, France and 43 more locations